Navigation Links
MSU scientists: Progesterone leads to inflammation
Date:8/19/2009

EAST LANSING, Mich. Scientists at Michigan State University have found exposure to the hormone progesterone activates genes that trigger inflammation in the mammary gland.

This progesterone-induced inflammation may be a key factor in increasing the risk of breast cancer.

Progesterone is a naturally occurring steroid hormone and promotes development of the normal mammary gland. Progesterone previously has been identified as a risk factor for breast cancer, and in a study published in the Journal of Steroid Biochemistry and Molecular Biology, MSU scientists examined the genes activated by progesterone and the effects of their activation in a mouse model system.

Exposure to progesterone in normal amounts and in normal circumstances causes inflammation, which promotes breast development. However, exposure to progesterone in menopausal hormone therapy is known to increase breast cancer risk.

"Progesterone turns on a wide array of genes involved in several biological processes, including cell adhesion, cell survival and inflammation," said physiology professor Sandra Haslam, co-author of the paper and director of the Breast Cancer and the Environment Research Center at MSU. "All of these processes may be relevant to the development of breast cancer."

The study shows progesterone significantly regulates 162 genes in pubertal cells, 104 genes in adult cells and 68 genes at both developmental stages. A number of these genes make small proteins, called chemokines, which control the process of inflammation.

Inflammation is a process where white blood cells move into a tissue. One type of white blood cell which moves to the breast during inflammation is a macrophage. Macrophages normally enter growing glands and help them develop, building blood vessels and reshaping growing tissue.

"Macrophages also may promote the development of tumors, such as breast cancer, as they make blood vessels to deliver nutrients and can clear the way for tumors to grow," Haslam said. "Long-term exposure to progesterone, such as that which occurs in menopausal hormone therapy, may encourage growth of tumors."

Haslam noted that as the link between progesterone and increased breast cancer risk was identified in recent years, women have been taking less hormone therapy after menopause and the rate of breast cancer in older women has gone down.

"This study reveals the targets of a specific form of the progesterone receptor, called PRA, in mammary cell development," said microbiology professor Richard Schwartz, a co-author of the paper and associate dean in the College of Natural Science. "The linkages identified provide targets for future work in reducing the influence progesterone has on developing breast cancer.

"Understanding the genes that regulate inflammation in the mammary gland will help us to better understand normal breast growth and also may help us devise better treatments for the abnormal growth in cancer."


'/>"/>

Contact: Jason Cody
codyja@msu.edu
517-432-0924
Michigan State University
Source:Eurekalert

Related medicine news :

1. Scientists: New technique identifies molecular biomarkers for disease
2. Emory researchers announce Phase III study of progesterone for traumatic brain injury
3. New Approach to Progesterone Supplementation in ART Revealed in Recently Published White Paper
4. Effectiveness of Progesterone in Reducing Preterm Births May Be Altered by Genetic Predisposition
5. Estrogen and progesterone receptor isoforms expression in the stomach of Mongolian gerbils
6. Progesterone Wont Shield Women Against Alzheimers
7. Vaginal progesterone gel may improve infant outcomes and...
8. Carnegie Mellon leads NSF initiative to develop modeling tools for disease and complex systems
9. Ten Years Later: O.I.S. Media Leads Physician Job Board Industry with Innovative Technology
10. LSTM leads project to develop HIV/AIDS strategy for Libya
11. Switch to digital mammography leads to increased cancer detection rates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... 2016 , ... "FCPX Overlay Glare is a tool that utilizes light found ... or complicated compositing," said Christina Austin - CEO of Pixel Film Studios. , ... lights that simulates the look of a glare. Just drag and drop to ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... been featured in SuperbCrew magazine, a leading online tech news platform connecting technology ... now featured on SuperbCrew.com, explores the state of enterprise mobility security today, and ...
(Date:12/5/2016)... ... , ... “Epilepsy Awareness,” which can be found at the ... about epilepsy, bearing down on the social stigma and lack of public education ... within their lifetime. With such a large percentage of people affected, it’s critically ...
(Date:12/5/2016)... ... December 05, 2016 , ... Eating disorders are equal ... Castlewood Treatment Centers has always been to promote the power of recovery, and ... possible. In that spirit, Castlewood has announced two new hires, both Outreach Directors ...
(Date:12/5/2016)... Shrewsbury, PA (PRWEB) , ... December 05, 2016 , ... ... of necessity for the betterment of both the smaller rider and the horse. Smaller ... performance. The Saddle Sidekick is designed to fit over a properly fitted western saddle ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Spain Glaucoma Surgery Devices Market Outlook to ... Surgery Devices Market Outlook to 2022", provides key market ... report provides value, in millions of US dollars, volume ... - Canaloplasty Micro Catheters and Glaucoma Drainage Devices. ... data for each of these market segements, and global ...
(Date:12/5/2016)... -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ), the ... and manufacturing data that support SB-525, its gene therapy program ... of the American Society of Hematology (ASH) being held in ... 2016. "We have developed an improved gene therapy ... highly competitive, and we remain on track to file an ...
(Date:12/5/2016)... Dec. 5, 2016  Cornerstone Pharmaceuticals, Inc., a ... data from two Phase I trials evaluating its ... 58th annual meeting of the American Society of ... . The two datasets show encouraging efficacy ... leukemia (AML) and T-cell non-Hodgkin,s lymphoma (T-cell NHL), ...
Breaking Medicine Technology: